# Revolo Biotherapeutics (Revolo Biotherapeutics Limited)

Private limited company registered in Cambridge, classed under “Research and experimental development on biotechnology”.

- Company number: 07828414
- Status: Active
- Type: Private limited company
- Incorporated: 31 October 2011
- Registered office: C/O Windsor House Station Court, Station Road, Great Shelford, Cambridge, CB22 5NE
- Location: Cambridge
- Activity: Research and experimental development on biotechnology

## Latest filed profit

Profit after tax in the year to 31 March 2026: **loss of £5.84m**, from its latest filed accounts.

Turnover, net assets, cash, staff, earlier years, ratios and owners are on the page for subscribers.

## Questions people ask

### What does Revolo Biotherapeutics do?

Private limited company registered in Cambridge, classed under “Research and experimental development on biotechnology”.

### How much turnover does Revolo Biotherapeutics make?

Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/revolo-biotherapeutics-07828414

### Is Revolo Biotherapeutics profitable?

No: it made a loss after tax of £5.84m in the year to 31 March 2026, its latest filed accounts.

### How many people work at Revolo Biotherapeutics?

Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/revolo-biotherapeutics-07828414

### Who runs and owns Revolo Biotherapeutics?

Its directors are Bcs Cosec Limited, Michael Albisser, Jones Woodrow Bryan, Isaac S. Cheng, Glen Thomas Giovannetti and 5 more. Its owners are shown to subscribers.

### Where is Revolo Biotherapeutics based?

Its registered office is C/O Windsor House Station Court, Station Road, Great Shelford, Cambridge, CB22 5NE, in Cambridge.

### When was Revolo Biotherapeutics founded?

Revolo Biotherapeutics Limited was incorporated on 31 October 2011.

### Is Revolo Biotherapeutics still trading?

The register lists Revolo Biotherapeutics Limited as active.

## Timeline

Recent filings and changes at Companies House.

- 2026-09-03: Total exemption full accounts made up to 31 March 2026
- 2026-08-17: Statement of capital following an allotment of shares on 18 June 2026 · GBP 629.9757 (and 29 more like it since 19 October 2017)
- 2026-08-03: Appointment of Mr Marek Stefan Gumienny as a director on 12 December 2025
- 2026-01-03: Total exemption full accounts made up to 31 March 2025
- 2025-10-22: Appointment of Mr Gunnar Jan Walstam as a director on 15 July 2025
- 2025-10-21: Registered office address changed from C/O Bcs Windsor House, Station Court Station Road Great Shelford Cambridgeshire CB22 5NE England to C/O Windsor House Station Court, Stati…
- 2025-05-30: Termination of appointment of David Peabody Southwell as a director on 19 May 2025
- 2025-03-05: Registration of charge 078284140002, created on 4 March 2025
- 2024-06-19: Total exemption full accounts made up to 31 March 2024
- 2024-03-27: Appointment of David Peabody Southwell as a director on 15 December 2023
- 2024-02-29: Termination of appointment of Jonathan Michael Norman Rigby as a director on 3 January 2024
- 2024-02-29: Appointment of Jones Woodrow Bryan as a director on 3 January 2024
- 2023-08-25: Total exemption full accounts made up to 31 March 2023
- 2023-02-09: Director's details changed for Ms Marla Susan Persky on 9 February 2023
- 2023-02-09: Director's details changed for Dr Babatunde Otulana on 9 February 2023
- 2023-02-09: Director's details changed for Mr Glen Thomas Giovannetti on 9 February 2023
- 2022-08-26: Group of companies' accounts made up to 31 March 2022
- 2022-06-27: Resolutions (and 3 more like it since 7 March 2018)
- 2022-05-26: Memorandum and Articles of Association (and 1 more like it since 28 September 2020)
- 2021-12-30: Group of companies' accounts made up to 31 March 2021
- 2021-08-14: Appointment of Dr Babatunde Otulana as a director on 1 August 2021
- 2021-07-22: Director's details changed for Ms Maria Susan Persky on 1 July 2021
- 2021-07-05: Appointment of Ms Maria Susan Persky as a director on 1 July 2021
- 2021-07-05: Appointment of Mr Glen Thomas Giovannetti as a director on 1 July 2021
- 2021-03-09: Appointment of Mr Michael Albisser as a director on 25 January 2021

---

Source: Companies House filings (Open Government Licence v3.0). Figures are as filed; nothing is estimated. Page: https://firmfacts.co/company/revolo-biotherapeutics-07828414